[cardiac automaticity is modulated]{.smallcaps} by both sympathetic and parasympathetic systems, and they are opposing in nature. Noradrenaline from sympathetic nerve efferents and adrenaline released into the circulation from the adrenal medulla accelerate heart rate, while ACh from vagal nerve efferents slows it down. The neurotransmitters and hormones act on the sinoatrial (SA) node to modulate an intrinsic pacemaking clock, the nature of which is controversial. The two main ideas are cycles of membrane pacemaker depolarization generated by hyperpolarization-activated cyclic nucleotide-gated cation channels (also known as *I*~f~ or *I*~h~) and/or the cyclical release of Ca^2+^ from intracellular stores via ryanodine receptors increasing inward sodium-calcium exchanger currents during the diastolic depolarization ([@B3], [@B6], [@B11], [@B13]). Noradrenaline and adrenaline bind to β~1~- and β~2~-adrenoreceptors and activate the stimulatory G protein (Gαs). Activated Gαs stimulates adenylyl cyclase, leading to an increase in cAMP level, which directly activates *I*~f~. This also leads to increased activity of PKA, resulting in modulation of downstream effectors, such as intracellular Ca^2+^-handling pathways, for example, phospholamban and the ryanodine receptor. In contrast, slowing of pacemaker depolarization occurs because of ACh binding to muscarinic M~2~ receptors and the activated Gαi\\o antagonizes the above pathways. In addition, the free Gβγ subunit released from Gαi\\o directly activates the G protein-gated inwardly rectifying K^+^ channel leading to membrane hyperpolarization. It is generally thought that all of these mechanisms contribute to some extent to modulating heart rate ([@B1]). These responses are all predicated on signaling networks initiated via Gαs and Gαi\\o, and the evidence of their importance is largely based on ex vivo studies of the sinoatrial node and pacemaker cells ([@B17]). Furthermore, in vivo heart rate shows variability not reproduced in such studies, and specific frequency components are attributed to sympathetic and vagally mediated cardiovascular reflexes ([@B22]). In addition, the issue is intricate at the molecular level. *Gnas* is a complex gene with the potential for generation of long and extralong isoforms ([@B27]). Furthermore, there are four main isoforms of Gαi\\o (Gαi1, Gαi2, Gαi3, and Gαo), and these are all widely expressed in most tissues with significant possibilities for redundancy ([@B5]). We have previously shown that mice with global genetic deletion of Gαi2 have abnormalities of heart rate regulation compatible with a role for that protein in the SA node, and thus, we focus here on that isoform ([@B29]). We have not previously investigated the contribution that Gαs makes to heart rate regulation, and this would not be possible in a strictly analogous fashion to our studies on the inhibitory G proteins as global genetic deletion of Gαs is embryonically lethal ([@B27]). Thus, we refined our strategy and sought to investigate the significance of Gαs and Gαi2 for physiological heart rate regulation in the sinoatrial node of the adult mouse using a conditional gene-targeting approach.

MATERIALS AND METHODS {#sec1}
=====================

 {#sec1-1}

### Murine husbandry. {#sec1-1-1}

Mice were maintained in an animal core facility under U.K. Home Office guidelines relating to animal welfare. All maintenance, breeding, and procedures were covered by project license PPL 70\\6732. All mice were kept in a temperature-controlled environment (21--23°C) with 12:12-h dark-light cycles. Animals were allowed access to standard rodent chow and water ad libitum. Mice were studied between 8 and 12 wk of age.

### Mouse strains and breeding and genotyping. {#sec1-1-2}

We interbred several mouse lines. We used mice in which the tamoxifen-inducible CreER^T2^ construct was "knocked" into the pacemaker channel HCN4 locus (HCN4-KiT, referred to as cre+ here), allowing for selective expression of cre recombinase in the cardiac conduction system following intraperitoneal administration of tamoxifen ([@B12]). We interbred these with "Gαs floxed" (Gαs^flx\\flx^) and "Gαi2 floxed" (Gαi2^flx\\flx^) mice. Gαs^flx\\flx^ mice have loxP sites placed in introns upstream and downstream of exon 1. Gαi2^flx\\flx^ mice have loxP sites placed in introns upstream of exon 2 and downstream of exon 4, and, thus, cre-mediated excision deletes exons 2, 3, and 4, which is equivalent to amino acids 40--155. A description of the targeting strategy to produce both lines of *flx/flx* mice has previously been published ([@B8], [@B26]). After successive rounds of breeding, we generated Gαs^flx\\flx^ cre+ mice, Gαi2^flx\\flx^ cre+ mice, and littermate "controls", which consisted of wild-type, cre+ only, and Gαs^flx\\flx^ or Gαi2^flx\\flx^ only genotypes. We observed no prominent differences among the latter groups and thus pooled them into single littermate control populations. Mice of both sexes were used in this study. The cre recombinase-expressing line is on a C57/BL6 background, Gαs^flx\\flx^ is on a C57/BL6 background, and the Gαi2^flx\\flx^ is on the 129/Sv background. Tamoxifen (Sigma) was freshly dissolved in sunflower oil, and 1 mg tamoxifen/25 g body wt ip was injected on five consecutive days. Mice were studied 10 days after the last dose.

Mice were tail clipped (∼2 mm) at 3--4 wk of age. Genomic DNA was isolated from tail clips. PCR-based genotyping was then performed on isolated DNA to confirm genotype of individual mice. One-hundred-and-fifty microliters of tail lysis buffer \[3.35 ml 2 M Tris·HCl pH 8.8, 1.66 ml 1 M (NH~4~)~2~SO~4~, 1.34 ml 0.5 M MgCl~2~, 0.5 ml Triton X-100, 92.2 ml H~2~O, and 1 ml β-mercaptoethanol\] was added, and the samples were heated to 100°C for 10 min in a heating block to denature mouse proteins. Samples were then cooled, and 5 μl of proteinase K (20 mg/ml) was added at 55°C for 12 h. Samples were then reheated to 100°C for a further 10 min and then spun at 13,000 rpm for 30 s in a tabletop centrifuge to sediment tail debris. One microliter of sample (mouse genomic DNA) was used per genotyping PCR. Identification of cardiac *Cre*^^ expression was determined using the following primer sets: HCN4Ki F5′-CCCGCGCTGGAGTTTCAATA-3′ and HCN4Ki R5′-CTTCGCCCAGTT GATCATGTG-3′. The presence of the *Cre* transgene was determined by the presence or absence of a *Cre* band (383bp). Gαs lox-P (floxed allele) genotyping was performed using the following primers: Gαs LoxF 5′-TTCGG TCTCG TCCCC TTAGT TG-3′ and Gαs LoxR 5′-AACAA ATCGC ACACC CCAGT GAGG-3′ using betaine (1.5 M) in the PCR master mix to obtain a WT band corresponding to ∼216 bp and a Gαs floxed band corresponding to ∼264 bp, respectively. Cre-mediated excision was confirmed by Gαs cre F 5′-GAGAGCGAGAGGAAGACAGC-3′and Gαs cre R 5′-AGCCCTACTCTGTCGCAGTC-3′ primers, which gives a band of ∼250 bp upon cre-mediated excision of exon 1. Gαi2 lox-P (floxed allele) genotyping was performed using the following primers: Gαi2 LoxF 5′-GGA GCC TGG ACT TTG CTT CTG ACC-3′ and Gαi2 LoxR 5′-GGC TAT GAT CCC AAA ACT CCC CG-3′ Gαi2 LoxF2 5′GTG GTA AGC CTG TGT GTT TGT GAG AG-3′. Using Gαi2 LoxF and Gαi2 LoxR as primers and a hotstart PCR strategy, we observed a ∼400-bp band corresponding to WT Gαi2 and a ∼500-bp band corresponding to the Gαi2 lox-P (floxed) allele. Using Gαi2 LoxF2 and Gαi2 LoxR, we observed that a ∼2,200-bp band in the absence of cre-mediated deletion of the "floxed" allele was present while a ∼400-bp band was produced after *Cre-*mediated excision of exons 2 to 4.

### Real-time RT-PCR on isolated SA nodal tissue. {#sec1-1-3}

RNA was isolated from the SA node and ventricle after tamoxifen treatment in both Gαs^flx\\flx^ cre+ or Gαi2^flx/flx^ cre+ and control mice using the RNeasy kit (Qiagen, Valencia, CA). cDNA was synthesized using the high-capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA). By using TaqMan gene expression assay (Assay ID: Mm03945887_s1), which spans exon 1, Gαs cDNA was quantified. Gαi2 cDNA was then quantified using the TaqMan gene expression assay kit using custom-designed primers spanning exon 2 boundary TGGAGAGTCAGGGAAGAGCA and exon 3 TAGACCACGGCACGGTACT (Applied Biosystems). All genes were assayed in triplicate, and relative gene expression was quantified using the comparative C~T~ method with GAPDH as the reference housekeeping gene ([@B19]).

### Radiotelemetry. {#sec1-1-4}

The telemetry probe (TEA-F20; Data Science International, St. Paul, MN) was implanted into mice to record ECG data in the conscious animal, as described previously ([@B29]). Briefly, tunnelled electrodes were secured in a lead II configuration connected to a telemetry device, which was implanted intra-abdominally using aseptic surgical technique. After a minimum of a week-long period of surgical recovery, ECG signals were acquired by radio-telemetry. To further examine heart rate modulation in vivo, we used pharmacological provocation with isoprenaline (3.0 μg/kg intraperitoneally) and carbachol (0.5 mg/kg intraperitoneally).

### Analysis of heart rate. {#sec1-1-5}

Initially, mean day and night heart rate (12 h light to dark cycle) were determined over 48 h from heart rate recorded for 15 s every 30 min. Surface ECG parameters, such as PR, QRS, and QT~c~ intervals, were also measured. Subsequently, we acquired R-R interval variability signal from ECG data streamed over 30 min at high sampling frequency (2 kHz), digitized and analyzed using a heart rate variability (HRV) extension module of CHART v7.0 (ADInstruments, Oxford, UK). A threshold-sensing algorithm for R-wave recognition was applied to detect all R-R intervals. Ectopic beats, which occurred only very rarely in this study, were excluded from analysis, and no averaged or interpolated beats were used to replace them. The data set of consecutive R-R intervals (typically, ∼12,000 sinus beats per mouse recording) was then analyzed in both the linear time and frequency domains. Time domain measurements include SD~n-n~, standard deviation of all R-R intervals in sinus rhythm ([@B25]), and root mean square SD, as the square root of the mean of the square difference between adjacent normal R-R intervals ([@B9], [@B18], [@B25]). Frequency domain analysis was performed after fast Fourier transform using 1,024 spectral points and a half overlap within a Welch window. For the frequency domain analysis, cut-off frequencies previously determined to be accurate for mice were used to divide signal into three major components of total power (TP), very low frequency (VLF \< 0.4 Hz), low frequency (LF 0.4--1.5 Hz), and high frequency (HF 1.5--4.0 Hz) ([@B9], [@B10], [@B28]). Normalization to exclude VLF was performed. Normalized low frequency (nLF) = LF/(TP − VLF) × 100 and normalized high frequency (nHF) = HF/(TP − VLF) × 100. The rate-corrected QT interval (QTc) is defined as QTc = QT/sqrt(R − R/100) with R-R measured in milliseconds. Heart rate after pharmacological challenge was determined over a 30-min time course and was measured when it had reached a steady state. The chronotropic effect of isoprenaline and carbachol was expressed as a percentage change of heart rate relative to baseline heart rate prior to drug administration. Intrinsic heart rate was determined in a similar way by administering atropine (1 mg/kg) and propanolol (1 mg/kg) together to achieve autonomic blockade in awake conscious mice with telemetry probes in situ. We also examined the effects of the drugs on HRV by recording 10 min of ECG tracing prior to drug administration and another 10 min after the heart rate had reached a steady state following drug administration.

### Statistical analysis. {#sec1-1-6}

Data are reported as means ± SE. Statistical significance of multiple treatments was determined by one- and two-way ANOVA followed by Dunnett\'s post hoc analysis, and statistical significance between two groups was determined by two-tailed Student\'s *t-*tests, as appropriate (GraphPad Prism v4). In all instances, *P* \< 0.05 was considered significant.

RESULTS {#sec2}
=======

 {#sec2-1}

### Generating mice with deletion of Gαs and Gαi2 in the conduction system. {#sec2-1-1}

Gαs^flx\\flx^ cre+, Gαi2^flx\\flx^ cre+ mice and littermate controls were generated as described above. We performed quantitative real-time RT-PCR on RNA extracted from the SA node and ventricle. We normalized measurements in the Gαs^flx\\flx^ cre+ and Gαi2^flx\\flx^ cre+ mice to expression in control mice (both after the administration of tamoxifen) in ventricle and SA node. There was a significant reduction in relative Gαs and Gαi2 RNA expression in the SA node but not ventricle {Gαs^flx\\flx^ cre+ SA node = 0.18 \[95% confidence interval (CI) 0.17--0.18\], ventricle = 1.01, (95% CI 0.99--1.03); and Gαi2^flx\\flx^ cre+ SA node = 0.11 (95% CI 0.09--0.24), ventricle = 1.04 (95% CI 0.80--1.36); *n* = 2 and 3 mice, respectively, in triplicate for all groups}. We also isolated genomic DNA from the tail, cardiac ventricle, and SA node and performed PCR, which confirmed cre-mediated deletion of exon 1 of *Gnas* and exons 2--4 in *Gnai2* in the SA node but not in the ventricle or tail (not shown).

### Effects on mean heart rate and diurnal variation. {#sec2-1-2}

Significant diurnal variation in heart rate (HR) was observed in Gαs^flx\\flx^ cre+ and Gαi2^flx\\flx^ cre+ mice before tamoxifen treatment but not after ([Fig. 1](#F1){ref-type="fig"}). There was a significant decrease in night-time HR in Gαs^flx\\flx^ cre+ mice, while there was a significant increase in day-time HR after tamoxifen treatment in Gαi2^flx\\flx^ cre+ mice ([Fig. 1](#F1){ref-type="fig"}). In contrast, control mice had preserved diurnal variation, and there was no significant change after tamoxifen treatment ([Fig. 1](#F1){ref-type="fig"}). We examined ECG parameters, and there was no significant difference in PR interval, QRS duration, or any evidence of spontaneous arrhythmia, such as heart block ([Fig. 1](#F1){ref-type="fig"} and [Table 1](#T1){ref-type="table"}). However, QTc was shorter in the Gαs^flx\\flx^ cre+ mice, but this was not investigated further in this study.

![ECG traces and diurnal variation of heart rate. *A* and *C*: representative ECG recordings and mean data for Gα~s~^fl\\flx^ cre+ (*n* = 8) and control (*n* = 8). *B* and *D*: for Gαi2^flx\\flx^, cre+ (*n* = 12) and control mice (*n* = 9). Values in *B* and *D* are expressed as means ± SE.](zh60151382440001){#F1}

###### 

Summarized ECG and HRV parameters for for Gαs^flx\\flx^ cre+ (*n* = 8) and control (*n* = 8) and for Gαi2^flx\\flx^ cre+ (*n* = 11) and control mice (*n* = 9) before and after tamoxifen

  Animal ID                 PR, ms         QRS, ms        QT~C,~ ms                                      RR, ms                                         SD nn, ms      RMS SD, ms     TP, ms^2^    VLF, ms^2^      LF, ms^2^     HF, ms^2^      nLF, nu                                        nHF, nu
  ------------------------- -------------- -------------- ---------------------------------------------- ---------------------------------------------- -------------- -------------- ------------ --------------- ------------- -------------- ---------------------------------------------- ---------------------------------------------
  Gαs flx cre before tam    32.50 ± 1.50   9.84 ± 1.1     62.28 ± 2.08                                   96.9 ± 2.46                                    2.92 ± 0.65    2.08 ± 0.51    131 ± 5.58   60.23 ± 9.2     39.53 ± 7.6   30.21 ± 7.9    55.16 ± 7.9                                    42.7 ± 7.52
  Gαs flx cre after tam     32.60 ± 1.22   9.92 ± 0.87    40.08 ± 2.07[\*](#T1F1){ref-type="table-fn"}   148.8 ± 4.05[\*](#T1F1){ref-type="table-fn"}   5.05 ± 1.00    7.14 ± 6.11    160 ± 82     85.12 ± 9.9     36.4 ± 8.9    37.35 ± 6.7    37.08 ± 3.82[\*](#T1F1){ref-type="table-fn"}   51.0 ± 4.60
  Gαs control before tam    34.96 ± 0.82   11.35 ± 0.66   67.75 ± 0.55                                   95.57 ± 0.064                                  14.75 ± 3.50   15.20 ± 3.63   297 ± 84     185.35 ± 15.2   42.23 ± 8.1   57.26 ± 12.7   48.34 ± 7.34                                   51.63 ± 7.33
  Gαs control after tam     38.81 ± 0.44   9.93 ± 0.27    67.05 ± 4.46                                   101.1 ± 0.95                                   12.51 ± 5.27   7.58 ± 0.62    200 ± 5.72   101.98 ± 5.9    48.6 ± 7.8    45.23 ± 7.2    49.27 ± 3.17                                   45.61 ± 4.44
  Gαi2 flx cre before tam   33.12 ± 0.49   10.41 ± 0.63   69.84 ± 4.98                                   113.1 ± 8.4                                    23.8 ± 7.57    11.7 ± 2.66    215 ± 81.4   97.7 ± 8.2      56.1 ± 9.2    49.5 ± 5.8     47.5 ± 6.08                                    43.35 ± 3.09
  Gαi2 flx cre after tam    34.06 ± 0.88   9.96 ± 0.37    69.21 ± 3.43                                   98.94 ± 7.8[\*](#T1F1){ref-type="table-fn"}    31.4 ± 6.64    13.6 ± 5.49    1302 ± 432   1201 ± 110      44.6 ± 7.8    31.2 ± 6.7     44.7 ± 5.97                                    30.21 ± 1.2[\*](#T1F1){ref-type="table-fn"}
  Gαi2 control before tam   35.07 ± 0.31   9.52 ± 0.452   61.63 ± 3.78                                   119.9 ± 10.1                                   11.80 ± 4.50   8.24 ± 0.81    134 ± 15.8   65.6 ± 12.7     25.01 ± 5.2   21.76 ± 5.9    36.6 ± 6.15                                    32.7 ± 2.08
  Gαi2 control after tam    36.33 ± 1.04   10.12 ± 0.35   62.36 ± 3.76                                   123.7 ± 1.7                                    5.778 ± 5.92   7.12 ± 0.97    248 ± 5.5    171.2 ± 10.2    27.1 ± 3.4    36.2 ± 7.2     35.4 ± 8.31                                    47.95 ± 3.55

*P* \< 0.05, repeated-measures one-way ANOVA.

The comparisons are between mice before and after tamoxifen (tam) in the various groups over the various parameters. HRV, heart rate variability; RMS, root mean square; TP, total power; VLF, very low frequency; LF, low frequency; HF, high frequency; nLF, normalized low frequency; nHF, normalized high frequency; nu, normalized units.

### Heart rate variability (HRV) analysis. {#sec2-1-3}

In both Gαs^flx\\flx^ cre+ and Gαi2^flx\\flx^ cre+ mice, HRV was altered after tamoxifen treatment. This was detectable in an individual mouse in power spectral density analysis ([Fig. 2](#F2){ref-type="fig"}). Specifically, there was a selective loss of normalized LF power in Gαs^flx\\flx^ cre+ mice, while, in contrast, in Gαi2^flx\\flx^ cre+ mice, there was a selective loss in normalized HF power ([Fig. 2](#F2){ref-type="fig"} and [Table 1](#T1){ref-type="table"}).

![Heart rate variability. Representative power spectrum density traces for Gαs^fl\\flx^ cre+ (*A*) and for Gαi2^flx\\flx^, cre+ (*B*) before and after tamoxifen administration. Mean normalized LF and HF for Gαs^fl\\flx^ cre+ (*C*; *n* = 8) and control (*n* = 8) and for Gαi2^flx\\flx^, cre+ (*D*; *n* = 11) and control (*n* = 9) mice.](zh60151382440002){#F2}

### Pharmacological modulation of heart rate. {#sec2-1-4}

We measured the chronotropic response after the administration of isoprenaline and carbachol in Gαs^flx\\flx^ cre+ and Gαi2^flx\\flx^ cre+ mice, respectively, after treatment with tamoxifen and compared this to control littermate mice ([Fig. 3](#F3){ref-type="fig"}). The positive chronotropic response to isoprenaline was abrogated but not abolished in Gαs^flx\\flx^ cre+ mice, and there was only a small nonsignificant reduction in the negative chronotropic response to carbachol in Gαi2^flx\\flx^ cre+ mice. There was no evidence of conduction block or arrhythmias occurring after drug administration.

![Response of heart rate to pharmacological agents. The percentage change in heart rate in Gαs^fl\\flx^ cre+ (*n* = 8) and control (*n* = 8) mice after isoprenaline administration (*top*) and for Gαi2^flx\\flx^, cre+ (*n* = 11) and control (*n* = 9) mice after carbachol administration (*bottom*). Values are expressed as means ± SE.](zh60151382440003){#F3}

### Intrinsic heart rate determination and HRV after atropine and propranolol administration. {#sec2-1-5}

For complete autonomic blockade, atropine and propanolol were administered together in Gαs^flx\\flx^ cre+ and Gαi2^flx\\flx^ cre+ mice before and after treatment with tamoxifen, and we compared their intrinsic heart rate and HRV to control littermate mice. In [Fig. 4*A*](#F4){ref-type="fig"} and [Table 2](#T2){ref-type="table"}, we show that that there was no change in intrinsic heart rate in both Gαs^flx\\flx^ cre+ and Gαi2^flx\\flx^ cre+. We also examined the effects of the combined atropine and propranolol treatment on HRV before and after tamoxifen treatment in the two groups of mice. We show the data after the administration of tamoxifen in Gαs^flx\\flx^ cre+ and Gαi2^flx\\flx^ cre+ mice. The administration of the two drugs led to a decrease in HRV across all of the frequency spectra ([Table 2](#T2){ref-type="table"}). There was no difference between the two genotypes in this behavior before (not shown) or after tamoxifen administration ([Fig. 4](#F4){ref-type="fig"} and [Table 2](#T2){ref-type="table"}). In [Fig. 4*B*](#F4){ref-type="fig"}, representative power spectra show abrogation of HF and LF power in both Gαs^flx\\flx^ cre+ and Gαi2^flx\\flx^ cre+ mice after atropine and propranolol administration ([Fig. 4*B*](#F4){ref-type="fig"}).

![Autonomic blockade. *A*: intrinsic heart rate after autonomic blockade with atropine and propranolol in Gαs^fl\\flx^ cre+ and Gαi2^flx\\flx^, cre+ mice (*n* = 6 in both groups). Values are expressed as means ± SE. *B*: representative power spectrum density (PSD) traces for Gαs^flx\\flx^ cre+ (*a* and *b*) and for Gαi2^flx\\flx^, cre+ (*c* and *d*) after prior treatment with tamoxifen and shown are the PSDs before (*left*, *a* and *c*) and after (*right*, *b* and *d*) atropine and propranolol administration.](zh60151382440004){#F4}

###### 

HRV parameters after atropine and propanolol (autonomic blockade) in Gαs^flx\\flx^ cre and Gαi2^flx\\flx^ cre mice

  Animal ID        *n*   Mean NN, ms   HR, bpm    SDNN, ms     RMS SD        TP, ms^2^                                       VLF, ms^2^                                    LF, ms^2^                                       LF, nu        HF, ms^2^                                    HF, nu       LF/HF
  ---------------- ----- ------------- ---------- ------------ ------------- ----------------------------------------------- --------------------------------------------- ----------------------------------------------- ------------- -------------------------------------------- ------------ -------------
  Gαi2 before AP   6     107.8 ± 7.1   535 ± 29   8.5 ± 2.9    4.87 ± 0.78   130 ± 23.1                                      86.2 ± 9.5                                    32.9 ± 9.7                                      75.1 ± 9.3    10.2 ± 3.2                                   23.3 ± 4.7   3.2 ± 0.84
  Gαi2 after AP    6     100.3 ± 9.6   597 ± 21   7.4 ± 1.9    3.89 ± 0.28   56.4 ± 10.7[\*\*](#T2F1){ref-type="table-fn"}   37.6 ± 5.68[\*](#T2F2){ref-type="table-fn"}   12.23 ± 5.4[\*\*](#T2F1){ref-type="table-fn"}   65.4 ± 10     5.2 ± 1.2[\*](#T2F2){ref-type="table-fn"}    27.6 ± 6.9   2.2 ± 0.35
  Gαs before AP    6     108.2 ± 7.2   555 ± 29   8.8 ± 3.8    5.78 ± 0.34   104 ± 8.9                                       81.09 ± 10.2                                  12.8 ± 4.8                                      55.65 ± 8.2   10.2 ± 2.4                                   44.3 ± 8.3   1.25 ± 0.32
  Gαs after AP     6     98.63 ± 10    606 ± 29   4.9 ± 0.64   3.33 ± 0.87   23.7 ± 9.8[\*\*](#T2F1){ref-type="table-fn"}    14.07 ± 6.6[\*](#T2F2){ref-type="table-fn"}   5.4 ± 1.4[\*](#T2F2){ref-type="table-fn"}       56.3 ± 9.7    3.1 ± 0.24[\*](#T2F2){ref-type="table-fn"}   32.5 ± 5.8   1.7 ± 0.34

AP, atropine and propanolol.

*P* \< 0.005,

*P* \< 0.05 before and after administration (repeated-measures one-way ANOVA).

DISCUSSION {#sec3}
==========

The main findings in this study are that selective deletion of Gαs and Gαi2 in the conduction system of the adult mouse impairs physiological heart rate regulation in the intact awake animal. Mice are nocturnal creatures active at night and more sedentary during the day; thus, they show a characteristic diurnal variation in heart rate. The higher mean rate at night reflects their increased movement and higher sympathetic drive. The selective deletion of Gαs in the conduction system results in loss of normal diurnal variation with the mice no longer tachycardic at night and thus relatively bradycardic compared with control. In contrast, although mice with selective deletion Gαi2 in the conduction system also lose normal diurnal variation, this occurs because they are relatively more tachycardic during the day, consistent with a decline in parasympathetic modulation of the SA node. We also determined the intrinsic heart using pharmacological blockade of the autonomic nervous system with atropine and propranolol. The intrinsic heart rate was not significantly different between the two groups of mice and the deletion of Gαs and Gαi2 in the SA node after tamoxifien administration did not change it. This confirms in vivo that the fundamental inherent pacemaker is not determined by Gαs and Gαi2 and pathways downstream of the G protein.

Heart rate shows physiological variation in rate in a number of frequency domains. In humans, a HF component (0.15 to 0.4 Hz), a LF component (0.04 to 0.15 Hz), and a very low-frequency component (\<0.04 Hz) are distinguished, and in the mouse, the frequencies defining each band are 10-fold higher ([@B22a], [@B24]). The high-frequency component is generally thought to reflect vagal input, while the low-frequency component reflects sympathetic and vagal input. However, the latter, in particular, is controversial ([@B22a]). Our data support a position broadly in which physiological Gαi2-mediated signaling in the SA node reflects the HF component and Gαs signaling reflects the LF component, and these two are distinct with little crosstalk. In terms of autonomic input, this would correspond to delineation between parasympathetic and sympathetic, accounting largely for most of HF and LF power, respectively. It is worth noting that we use a standard normalization procedure, and once this is done, the correlation between LF and sympathetic activity is clearer ([@B22a]). Defining the molecular correlates underlying HRV is not simply of academic interest. HRV is a widely used noninvasive technique to assess autonomic tone, particularly in human studies, and has prognostic significance in patients after myocardial infarction, with hypertension and in many other diseases ([@B22a], [@B23]).

There are some interesting comparisons in HRV data between the mice with conditional genetic deletion of Gαs and Gαi2 in the SA node and those after drug administration and in mice with global genetic deletion of Gαi2. The global genetic deletion of Gαs in mice is embryonically lethal, and thus, the heart rate phenotype of this animal cannot be studied ([@B27]). The global genetic deletion of Gαi2 and the administration of atropine, tertiapin, propranolol, and atropine suppressed HRV in the time domain and in the frequency domain and generally had effects across all three frequency spectra ([@B29]). In contrast, the effect of conditional deletion in the SA node was more subtle and was revealed when variation in VLF was removed by the normalization of HF and LF. It is worth noting that VLF accounts for the majority of power in the HRV signal. There are some technical caveats that need to be considered. Nonstationarities in the HRV signal can be a confounding factor and, for example, monitoring HRV throughout the day as human subjects go about their daily lives may overestimate the sympathetic contribution ([@B4], [@B15]). We seek to minimize using the recommended approaches, i.e., monitoring the mice at rest at a defined time during the day for a short recording period. Furthermore, it is important that the mice are allowed to recover from surgery (generally 7--10 days) and resume normal activity after probe implantation before measurements are made. These factors are the same between our current and previous studies, and thus, the differences are likely real. Factors likely responsible for the differences are those that lie outside the SA node. For example, effects in the central and peripheral nervous system also have an important influence on HRV. Gαi2 is expressed in the nervous system, and drugs, such as propranolol, with a high lipophilicity cross the blood-brain barrier. In this regard, the HCN4-KiT mouse does not lead to deletion of genes in the brain after the administration of tamoxifen ([@B12]).

It is important to clearly define in vivo the molecular isoforms responsible for physiological heart rate regulation. Thus, the *Gnas* gene locus is complex with imprinting (although not in cardiac tissues) and the potential for the generation of a long and extra-long isoforms, whose roles in signaling are not clear ([@B27]). The data here implicate canonical Gαs, although the mice do not distinguish long and short forms of Gαs. XLαs, which is a distinct paternal Gαs isoform from the paternal allele, is not affected in these mice. Our results are consistent with recent studies in pigs using adenoviral transfer of small interfering RNA to Gαs ([@B14]). Furthermore, there has been debate about the inhibitory G protein isoform underlying physiological heart rate modulation, and we have discussed this in considerable detail elsewhere ([@B1], [@B29]). The fundamental issue is that a wide variety of different approaches and experimental systems have been used. Our data here support an important role for Gαi2 but do not exclude a contribution from other isoforms (see below). We believe that the genetic and in vivo monitoring approach that we have adopted is one of the better combinations to address such integrative physiological questions.

A potential qualification with our data is the response to the pharmacological agents. After selective deletion of Gαs in the conduction system, the response to isoprenaline was significantly attenuated but not abolished, while with Gαi2 deletion, the heart rate-slowing response to carbachol is relatively well preserved. This contrasts with the situation in the global knockout of Gαi2, where it was significantly attenuated. The tests with isoprenaline and carbachol are a pronounced pharmacological challenge in that, for example, with carbachol, the heart rate falls to levels a long way below that normally seen physiologically, even in normal situations, such as sleep. It is known that the sinoatrial node is actually quite an extensive and heterogenous structure and that the primary pacemaking site moves from one region to another, as the sympathovagal balance changes ([@B17], [@B21]). Thus, it is possible that the pacemaking site shifts to a small region that is not solely dependent on the deleted G protein or a site in which the HCN4 promoter driven cre-mediated deletion is not so complete. A further consideration is that the dose of isoprenaline, while leading to a close to maximal heart rate response, is considered to be relatively low ([@B20]). It is possible that the variances in behavior between carbachol and isoprenaline are accounted for by differences in the relative position of the single dose on the dose-response curve.

There is great interest in the role that heart rate per se has in the outcome of heart failure after the use of ivabridine in the SHIFT trial ([@B7]). These mouse lines may be useful resources in addressing this interesting question, as they have changes in heart rate generated independently of pharmacological manipulation. While the mouse is valuable for understanding the molecular basis of cardiac function, especially given the relative ease and sophistication of the manipulation of the genome, it has limitations. The mouse heart rate is ∼10-fold higher than that in a human, and there are differences in ion channel expression in various cardiac cells across the species. In addition, rat and mouse show a negative force-frequency relationship, while it has a positive slope in larger mammals, such as rabbits ([@B16]). However, it is clear that in the range of normal physiological heart rates, Gαs and Gαi2 in the sinoatrial node have an important role in determining normal heart rate and normal physiological variability.
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